Inhibrx Biosciences (INBX) Consolidated Net Income (2023 - 2025)
Historic Consolidated Net Income for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$35.3 million.
- Inhibrx Biosciences' Consolidated Net Income rose 1962.43% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 10943.65%. This contributed to the annual value of $1.7 billion for FY2024, which is 80395.57% up from last year.
- Per Inhibrx Biosciences' latest filing, its Consolidated Net Income stood at -$35.3 million for Q3 2025, which was up 1962.43% from -$28.7 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Consolidated Net Income registered a high of $1.9 billion during Q2 2024, and its lowest value of -$92.0 million during Q4 2023.
- In the last 3 years, Inhibrx Biosciences' Consolidated Net Income had a median value of -$45.5 million in 2023 and averaged $139.0 million.
- As far as peak fluctuations go, Inhibrx Biosciences' Consolidated Net Income soared by 404884.6% in 2024, and later tumbled by 10154.22% in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' Consolidated Net Income stood at -$92.0 million in 2023, then skyrocketed by 47.96% to -$47.9 million in 2024, then increased by 26.34% to -$35.3 million in 2025.
- Its Consolidated Net Income stands at -$35.3 million for Q3 2025, versus -$28.7 million for Q2 2025 and -$43.3 million for Q1 2025.